The acquisition will add to Isto Biologics’ portfolio of orthopedic grafts and bring TheraCell’s patented TheraFuze DBF technology to Isto’s Influx product line. Isto Biologics focuses on bone regeneration and cell-based therapies for orthopedics.
Isto Biologics is backed by private equity firm Thompson Street Capital Partners.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
